Angle PLC Reports H1 2025 Results with Progress in Pharma and Medtech Collaborations

Technology milestone: DNA Dual Analysis on Illumina NGS

ANGLE launched a workflow that simultaneously analyses CTC-DNA and ctDNA from a single blood draw using Illumina Next Generation Sequencing. This is positioned as unique and is now available as a clinical lab service and as a protocol for independent centres.

Early data are striking. In a 27-patient lung cancer study using a 79-gene panel, mutation calls split as follows:

• 53% found in CTCs alone
• 36% found in ctDNA alone
• 11% found in both

The takeaway is that CTC-DNA and ctDNA provide distinct and complementary insights. For pharma, that could mean better patient stratification and resistance mechanism tracking. For healthcare systems already running Illumina panels, it offers a way to add CTCs without changing platforms. ANGLE says large pharma and the NHS have shown interest in evaluating this in clinical trials.

Assay menu expansion and pathway to recurring use

ANGLE continues to build out its assay catalogue around Parsortix-captured CTCs:

• AR assay for prostate cancer, enabling repeat assessment of AR expression.
• DDR assays including γH2AX, pKAP1 and micronuclei to assess DNA damage and repair over time.
• Portrait PD-L1 and Portrait Flex imaging assays for broad phenotypic detection and custom biomarkers.
• HER2 assay kit with BioView – development completed, with validation continuing after promising AACR 2025 data showing changing CTC HER2 status can be detected.

The strategic pitch is clear: move tissue-based, single-use diagnostics to repeat blood-based tests using intact CTCs. That creates potential recurring revenue for partners and positions Parsortix for large-scale adoption once clinical utility is proven.

Footprint, research outputs and NHS engagement

The installed base has grown to over 270 Parsortix systems, with 248,000 cumulative samples processed by 30 June 2025. Academic traction remains strong: 11 peer-reviewed papers were published in the period, taking the total to 115 from 45 independent centres.

Notably, research in Nature Medicine led to a spin-out targeting CTC clusters to arrest metastasis, with Parsortix central to patient stratification. Further publications from ETH Zurich and others underscore ANGLE’s role in CTC biology and translational research.

ANGLE is also in encouraging discussions with the UK NHS about major clinical studies as part of the NHS 10 Year Health Plan. That could provide the prospective clinical utility data that unlocks broader clinical adoption.

What could move the shares next

• New contracts and collaborations – management expects to announce multiple high-profile deals with large pharma, medtech, and downstream analysis partners in the coming months.
• Myriad Genetics progress – evidence of concordance with tissue and early service revenue would be a meaningful de-risking step.
• NHS study announcements – formal trials would address the commercial gap around clinical utility.
• Cash events – receipt of the £1.0 million tax credit and clarity on further funding options.
• Revenue conversion – conversion of up to £0.8 million booked for future periods and any uplift if macro delays ease.

Risks and realities

• Funding – despite runway into Q1 2026, the going concern statement makes it clear that additional funding will be required. Timing and terms matter.
• Macro-driven delays – customer budget freezes and US policy or tariff uncertainty could keep pushing revenues into 2026.
• Execution – moving from successful pilots to scaled commercial adoption requires robust clinical evidence and partner alignment.

My view: credible delivery, tight runway

ANGLE delivered on big-name pharma contracts, broadened its assay offering, and unveiled a distinctive Illumina-based dual DNA workflow that could set it apart. The Myriad collaboration is a timely bridge to clinical adoption and recurring use cases. On the flip side, revenues are light, and the company openly flags a need for additional funding before Q1 2026.

For investors, this is a classic execution-versus-financing story. Near-term newsflow on collaborations, NHS studies, and the Myriad read-across could be catalytic. But keep an eye on cash, contract timing, and the pace at which booked opportunities convert to revenue.

Jargon buster

• CTC – circulating tumour cell, an intact cancer cell found in the bloodstream.
• ctDNA – circulating tumour DNA, fragments of tumour DNA found in blood.
• NGS – next generation sequencing, high-throughput DNA sequencing.
• Companion diagnostic – a test used to identify patients who are likely to benefit from a specific drug.

Further reading

• ANGLE corporate presentations and webcast access: Investor Centre
• Glossary of frequently used terms: ANGLE glossary